Research and development of innovative cardioprotective modality by nanoparticle-mediated targeting to inflammatory monocytes and IR myocardium

2015 Fiscal Year Final Research Report

• Project/Area Number: 25293185
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: Kyushu University
• Principal Investigator: Egashira Kensuke 九州大学, 学内共同利用施設等, 教授 (60260379)
• Co-Investigator(Renkei-kenkyūsha): MATOBA Tetsuya 九州大学病院, 循環器内科, 講師 (20448426)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 虚血再灌流傷害 / 急性心筋梗塞 / 再灌流療法 / ナノテクノロジー / ドラッグ・デリバリー・システム

Outline of Final Research Achievements

In rat and pig IR models, poly(lactic acid/glycolic acid) (PLGA) nanoparticle incorporating FITC accumulated in the IR myocardium through enhanced vascular permeability, and in CD11b-positive leukocytes in the IR myocardium and peripheral blood after intravenous treatment. Intravenous treatment with PLGA nanoparticle containing pitavastatin (Pitavastatin-NP, 1 mg/kg) at reperfusion reduced MI size after 24 hours and ameliorated left ventricular dysfunction 4-week after reperfusion; by contrast, pitavastatin alone (as high as 10 mg/kg) showed no therapeutic effects.
In mouse model IR model, treatment with nanoparticles incorporated with CsA (CsA-NP) pioglitazone, irbesartan and etc at the onset of reperfusion enhanced cardioprotection against IR injury by those drugs alone.
Therefore, this nanotechnology-based platform can be developed as an innovative cardioprotective modality that may advance currently unsatisfactory reperfusion therapy for AMI.

Free Research Field

循環器内科学